ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 8 November 2024 ASH 2024 preview – CD19 back on the agenda Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T. 7 November 2024 Next for Trodelvy: small-cell lung cancer Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC. 6 November 2024 Tango missteps in PRMT5 The company abandons TNG908, but is still all in on the troubled target. 6 November 2024 SITC 2024 – Arcus springs a TIGIT surprise Reports of Arc-10's failure are greatly exaggerated, the company argues. 5 November 2024 ASH 2024 preview – Arcellx disappoints An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel. 4 November 2024 SITC 2024 preview – duelling TIGIT duds Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers. Load More Recent Quick take ASCO 2024 – acasunlimab impresses on overall survival 2 June 2024 ASCO 2024 – USP1 lives on, for now 2 June 2024 ASCO 2024 – Pfizer’s KAT6 inhibitor purrs 2 June 2024 ASCO 2024 – two more Echelon-3 surprises 2 June 2024 ASCO 2024 – AbbVie sees SEZ6 improvement 1 June 2024 Ikena rolls over on Hippo 29 May 2024 Setanaxib looks like small beer for Calliditas’s Japanese suitor 28 May 2024 No dato-dxd surprise in squamous lung cancer 28 May 2024 ASCO 2024 preview – first look at Kelun’s registrational TROP2 dataset 23 May 2024 Vizimpro delivers for Pfizer 21 May 2024 Load More Most Popular